CPIX Cumberland Pharmaceuticals Inc
Price (delayed)
$4.28
Market cap
$59.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.46
Enterprise value
$62.39M
Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at
Highlights
The net income rose by 40% QoQ but it fell by 3.2% YoY
Cumberland Pharmaceuticals's EPS has increased by 40% from the previous quarter but it has decreased by 4.5% YoY
CPIX's equity is down by 23% year-on-year and by 8% since the previous quarter
The quick ratio has decreased by 6% YoY
Key stats
What are the main financial stats of CPIX
Market
Valuations
Earnings
Shares outstanding
13.97M
Market cap
$59.78M
Enterprise value
$62.39M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
1.59
EV/EBIT
N/A
EV/EBITDA
426.28
EV/Sales
1.65
Revenue
$37.87M
Gross profit
$31.28M
Operating income
-$6.43M
Net income
-$6.48M
EBIT
-$5.9M
EBITDA
$146,367
Free cash flow
-$791,900
Per share
Balance sheet
Liquidity
EPS
-$0.46
EPS diluted
-$0.46
Free cash flow per share
-$0.06
Book value per share
$1.63
Revenue per share
$2.69
TBVPS
$4.03
Total assets
$75.58M
Total liabilities
$53.04M
Debt
$20.57M
Equity
$22.85M
Working capital
$4.83M
Debt to equity
0.9
Current ratio
1.15
Quick ratio
0.94
Net debt/EBITDA
17.82
Margins
Efficiency
Dividend
EBITDA margin
0.4%
Gross margin
82.6%
Net margin
-17.1%
Operating margin
-17%
Return on assets
-8.3%
Return on equity
-25.5%
Return on invested capital
-18.2%
Return on capital employed
-13.4%
Return on sales
-15.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPIX stock price
How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
-1.83%
1 week
-1.15%
1 month
-11.93%
1 year
147.4%
YTD
80.59%
QTD
1.18%
Financial performance
How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$37.87M
Gross profit
$31.28M
Operating income
-$6.43M
Net income
-$6.48M
Gross margin
82.6%
Net margin
-17.1%
The company's operating margin rose by 42% QoQ and by 30% YoY
The company's net margin rose by 42% QoQ but it fell by 8% YoY
The net income rose by 40% QoQ but it fell by 3.2% YoY
CPIX's operating income is up by 40% since the previous quarter and by 33% year-on-year
Growth
What is Cumberland Pharmaceuticals's growth rate over time
Valuation
What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.63
P/S
1.59
EV/EBIT
N/A
EV/EBITDA
426.28
EV/Sales
1.65
Cumberland Pharmaceuticals's EPS has increased by 40% from the previous quarter but it has decreased by 4.5% YoY
CPIX's P/B is 198% above its 5-year quarterly average of 0.9 and 168% above its last 4 quarters average of 1.0
CPIX's equity is down by 23% year-on-year and by 8% since the previous quarter
The stock's price to sales (P/S) is 170% more than its last 4 quarters average of 0.6 and 80% more than its 5-year quarterly average of 0.9
The revenue has contracted by 4.3% YoY but it has grown by 2.9% from the previous quarter
Efficiency
How efficient is Cumberland Pharmaceuticals business performance
Cumberland Pharmaceuticals's ROS has increased by 44% from the previous quarter but it has decreased by 11% YoY
The company's return on equity fell by 41% YoY but it rose by 37% QoQ
CPIX's return on invested capital is up by 41% since the previous quarter but it is down by 10% year-on-year
The ROA has grown by 39% from the previous quarter but it has contracted by 15% YoY
Dividends
What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPIX.
Financial health
How did Cumberland Pharmaceuticals financials performed over time
The total assets is 43% greater than the total liabilities
The current ratio is down by 10% year-on-year
The total assets has declined by 8% year-on-year
The company's debt is 10% lower than its equity
The debt to equity has grown by 45% YoY and by 3.4% from the previous quarter
CPIX's equity is down by 23% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.